SCTbio
Prague, Czech Republic
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
81.6
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
✓ EMA GMP (5)
○ MHRA GMP
Quick Facts: SCTbio
- Signal Score
- 81.6/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100 — Clean EMA record: 5 active GMP certificates (no deductions)
- Headquarters
- Prague, Czech Republic
- Modalities
- CAR-T, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About SCTbio
Pure-play cell therapy CDMO. Part of PPF Biotech network.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Clean EMA record: 5 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP
Clean EMA record: 5 active GMP certificates (no deductions)
FDA InspectionsNo US records on file
EMA GMP Certificates5 on record
Clean EMA record: 5 active GMP certificates (no deductions)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
68.0
Parent company: PPF Group
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: PPF Group
Financial assessment: 68.0/100
Capacity
63.0
2 manufacturing sites
Sites: Prague, Czech Republic, Boston, MA
Source: company profiles (manufacturing sites, modality breadth)
2 manufacturing sites
2 manufacturing sites
SCTbio EMA GMP Compliance 5 certificates
2026-03
2026-03
2024-01
2023-11
2022-07
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| sukls420762/2025 | SCT Cell Manufacturing s.r.o. | Czechia | 2026-03-19 | COMPLIANT |
| sukls420756/2025 | SCT Cell Manufacturing s.r.o. | Czechia | 2026-03-18 | COMPLIANT |
| sukls261199/2023 | SCT Cell Manufacturing s.r.o. | Czechia | 2024-01-15 | COMPLIANT |
| sukls261141/2023 | SCT Cell Manufacturing s.r.o. | Czechia | 2023-11-30 | COMPLIANT |
| sukls139841/2022 | SCT Cell Manufacturing s.r.o. | Czechia | 2022-07-14 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Frequently Asked Questions About SCTbio
Does SCTbio hold EMA or MHRA GMP certificates?
CDMO Signal tracks 5 EMA GMP certificates for SCTbio.
What is SCTbio's CDMO Signal Score?
SCTbio has a Signal Score of 82/100, based on quality, operations, financial stability, and capacity data.
Evaluating SCTbio for a manufacturing program?
Use the free AI matchmaker to compare SCTbio against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
Compare SCTbio with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.